Safety and Side Effects of Rifampin versus Isoniazid in Children

Diallo, Tidiane; Adjobimey, Mênonli; Ruslami, Rovina; Trajman, Anete; O, Sow; Baah, Joseph Obeng; Marks, Guy B.; Long, Richard; Elwood, Kevin; Zielinski, David; Gninafon, M.; Wulandari, Dewi; Apriani, Lika; Valiquette, Chantal; Fregonese, Federica; Hornby, Karen; Li, Peizhi; Hill, Philip C.; Schwartzman, Kevin; Benedetti, Andrea; Menzies, Dick

doi:10.1056/nejmoa1714284

Cited by 134 publications

(101 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Isoniazid, taken daily for six or nine months, is associated with a reduction in risk of future tuberculosis disease in all age groups and has been the mainstay of treatment for M.tb infection for fifty years. 42 Newer alternatives to the six or nine month isoniazid regimen include three months of daily therapy with both isoniazid and rifampicin, 43 three months of weekly isoniazid and rifapentine, 44 four months of daily rifampicin 45 and one month of daily isoniazid and rifapentine. 46 Compared to nine-month regimens, shorter regimens are associated with improved adherence -a particular issue in adolescents 47 -and at least equivalent efficacy, with no increase in adverse events.…”

Section: Mtb Infectionmentioning

confidence: 99%

“…46 Compared to nine-month regimens, shorter regimens are associated with improved adherence -a particular issue in adolescents 47 -and at least equivalent efficacy, with no increase in adverse events. 36,45 Tuberculosis prevention has been historically neglected in high tuberculosis burden settings due to resource constraints. 47 The Sustainable Development Goals place new emphasis on prevention, as demonstrated in both the End TB Strategy 48 and in the WHO/UNICEF Roadmap Towards Ending Tuberculosis in Children and Adolescents.…”

Section: Mtb Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Adolescent tuberculosis

Snow

Cruz

Seddon

et al. 2020

The Lancet Child & Adolescent Health

119

View full text Add to dashboard Cite

Adolescence is characterised by a dramatic increase in the incidence of tuberculosis, a fact that has been appreciated since the early 20 th century. The majority of the world's adolescents live in low and middle-income countries where tuberculosis remains common, and where they comprise one quarter of the population. Despite this, adolescents have not yet been addressed as a distinct population in tuberculosis policy or within tuberculosis treatment services, and emerging evidence suggests that current models of care do not meet their needs.This article reviews current knowledge about tuberculosis in adolescence with a focus on the management of infection and disease, including HIV co-infection and rifampicin-resistant tuberculosis. Recent progress in vaccine development is outlined and important directions for future research are highlighted. Search strategy and selection criteriaThis was a narrative review of the literature on adolescent tuberculosis, informed by expert opinion and clinical experience. We reviewed the English-and Spanish-language literature for studies on adolescent tuberculosis to identify case series documenting clinical presentation and treatment outcomes. We searched PubMed with the following string on 19August 2019: ('tuberculosis'[Title]) AND ('adolescent'[TIAB]). The search returned 210 results, of which 11 were eligible for inclusion (Table 1), and we identified three additional studies from reference lists, for a total of 14 studies. Studies reporting solely on prevalence or where data from adolescents was aggregated with those of younger children or adults were excluded. Data were extracted regarding major site(s) of disease, percent of adolescents with microbiologic confirmation, adverse drug reactions, and final treatment outcomes.

show abstract

Section: Mtb Infectionmentioning

confidence: 99%

Section: Mtb Infectionmentioning

confidence: 99%

Adolescent tuberculosis

Snow

Cruz

Seddon

et al. 2020

The Lancet Child & Adolescent Health

119

View full text Add to dashboard Cite

show abstract

“…The bitter taste of isoniazid and the size of the tablet provided further difficulties when encouraging children to take their medication in multiple studies . Shorter, 3–4‐month regimens combining rifamycin antibiotics and isoniazid have recently been developed and shown to be safe and effective in children with improved adherence, while dissolvable, flavoured dose combinations have been used in active TB treatment since 2016 . Producing and making use of similar formulations in IPT would be an achievable and beneficial step along the pathway to better treatment options for latent TB in children.…”

Section: Discussionmentioning

confidence: 99%

Barriers to the implementation of isoniazid preventive therapy for tuberculosis in children in endemic settings: A review

Grace

2019

J Paediatrics Child Health

View full text Add to dashboard Cite

Isoniazid preventive therapy is one of the key interventions in reducing the risk of active disease among children exposed to tuberculosis. However, initiation and maintenance of this treatment is poor in many areas. This review summarises the existing literature on barriers to implementation of isoniazid preventive therapy for tuberculosis in children in endemic settings. MEDLINE, EMBASE and CINAHL databases were used to search for primary research studies published between 1998 and 2018, specifically mentioning isoniazid preventive therapy, tuberculosis and children. Barriers identified in most study settings included absence of parental risk perception, health‐care worker knowledge gaps and treatment access. Focusing on patient‐centred care, enhancing community and health‐care worker education and securing stable medication supply to effectively deliver this therapy is crucial in order to reduce childhood morbidity and mortality from tuberculosis.

show abstract

“…However, adherence to isoniazid is suboptimal. Canadian researchers randomised children <18 years with LTBI to 4 months of once‐daily oral rifampicin or 9 months of once‐daily oral isoniazid . Children given rifampicin ( n = 422) were significantly more likely than those given isoniazid ( n = 407) to complete therapy (85.3 vs. 76.4%).…”

mentioning

confidence: 99%

Rifampicin versus isoniazid for tuberculosis chemoprophylaxis

2019

J Paediatrics Child Health

View full text Add to dashboard Cite

Safety and Side Effects of Rifampin versus Isoniazid in Children

Cited by 134 publications

References 21 publications

Adolescent tuberculosis

Adolescent tuberculosis

Barriers to the implementation of isoniazid preventive therapy for tuberculosis in children in endemic settings: A review

Rifampicin versus isoniazid for tuberculosis chemoprophylaxis

Contact Info

Product

Resources

About